ScoreWhy is Citius Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Positive results in Dec 25
- NET PROFIT(HY) Higher at USD -16.18 MM
- RAW MATERIAL COST(Y) Fallen by -6,545% (YoY)
- NET SALES(9M) Higher at USD 3.94 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -53.01%, its profits have risen by 4%
4
Majority shareholders : Mutual Funds
5
Below par performance in long term as well as near term
- Along with generating -53.01% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Citius Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Citius Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Citius Pharmaceuticals, Inc.
-53.01%
-0.74
127.90%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
37.64%
EBIT Growth (5y)
-24.29%
EBIT to Interest (avg)
-33.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.05
Tax Ratio
1.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.85%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.25
EV to EBIT
-0.35
EV to EBITDA
-0.36
EV to Capital Employed
0.18
EV to Sales
3.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-51.11%
ROE (Latest)
-48.59%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
NET PROFIT(HY)
Higher at USD -16.18 MM
RAW MATERIAL COST(Y)
Fallen by -6,545% (YoY
NET SALES(9M)
Higher at USD 3.94 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 0.08 times
DEBTORS TURNOVER RATIO(HY)
Highest at 1.95 times
EPS(Q)
Highest at USD -0.38
-6What is not working for the Company
INTEREST(9M)
At USD 0.42 MM has Grown at inf%
OPERATING CASH FLOW(Y)
Lowest at USD -34.84 MM
Here's what is working for Citius Pharmaceuticals, Inc.
Net Sales
At USD 3.94 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -16.18 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.38
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 0.08 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 1.95 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 3.94 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -6,545% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Citius Pharmaceuticals, Inc.
Interest
At USD 0.42 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -34.84 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
